☰

Susan Browne, PhD - Publications

Affiliations: 
Merck Research Laboratories, West Point, Pennsylvania, Lansdale, PA, United States 
Tree Info Grants Similar researchers PubMed Report error

37 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2010 Hyson HC, Kieburtz K, Shoulson I, McDermott M, Ravina B, de Blieck EA, Cudkowicz ME, Ferrante RJ, Como P, Frank S, Zimmerman C, Cudkowicz ME, Ferrante K, Newhall K, ... ... Browne SE, et al. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 1924-8. PMID 20669312 DOI: 10.1002/mds.22408  0.357
2008 Browne SE. Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models. Annals of the New York Academy of Sciences. 1147: 358-82. PMID 19076457 DOI: 10.1196/annals.1427.018  0.371
2007 Constantinescu R, McDermott MP, Dicenzo R, de Blieck EA, Hyson HC, Beal MF, Bednarczyk EM, Bogdanov M, Metakis LJ, Browne SE, Lorenzo BJ, Ravina B, Kieburtz K. A randomized study of the bioavailability of different formulations of coenzyme Q(10) (ubiquinone). Journal of Clinical Pharmacology. 47: 1580-6. PMID 17925590 DOI: 10.1177/0091270007307571  0.304
2007 Kim YS, Choi DH, Block ML, Lorenzl S, Yang L, Kim YJ, Sugama S, Cho BP, Hwang O, Browne SE, Kim SY, Hong JS, Beal MF, Joh TH. A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 21: 179-87. PMID 17116747 DOI: 10.1096/Fj.06-5865Com  0.747
2006 Browne SE, Beal MF. Oxidative damage in Huntington's disease pathogenesis. Antioxidants & Redox Signaling. 8: 2061-73. PMID 17034350 DOI: 10.1089/Ars.2006.8.2061  0.56
2006 Saydoff JA, Garcia RA, Browne SE, Liu L, Sheng J, Brenneman D, Hu Z, Cardin S, Gonzalez A, von Borstel RW, Gregorio J, Burr H, Beal MF. Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease. Neurobiology of Disease. 24: 455-65. PMID 17011205 DOI: 10.1016/J.Nbd.2006.08.011  0.537
2006 Browne SE, Yang L, DiMauro JP, Fuller SW, Licata SC, Beal MF. Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. Neurobiology of Disease. 22: 599-610. PMID 16616851 DOI: 10.1016/J.Nbd.2006.01.001  0.653
2005 Kim SY, Marekov L, Bubber P, Browne SE, Stavrovskaya I, Lee J, Steinert PM, Blass JP, Beal MF, Gibson GE, Cooper AJ. Mitochondrial aconitase is a transglutaminase 2 substrate: transglutamination is a probable mechanism contributing to high-molecular-weight aggregates of aconitase and loss of aconitase activity in Huntington disease brain. Neurochemical Research. 30: 1245-55. PMID 16341586 DOI: 10.1007/S11064-005-8796-X  0.467
2005 Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubilus JK, Ryu H, Langley B, Ratan RR, Ferrante RJ, Beal MF. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. The Journal of Biological Chemistry. 280: 556-63. PMID 15494404 DOI: 10.1074/Jbc.M410210200  0.774
2005 DiMauro JP, Yang L, Fuller SW, Browne SE. Metabolic abnormalities precede pathologic changes in the G93A SOD1 mouse model of ALS Journal of Cerebral Blood Flow & Metabolism. 25: S64-S64. DOI: 10.1038/Sj.Jcbfm.9591524.0064  0.628
2004 Klivenyi P, Gardian G, Calingasan NY, Yang L, von Borstel R, Saydoff J, Browne SE, Beal MF. Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity. Neuromolecular Medicine. 6: 87-92. PMID 15970626 DOI: 10.1385/Nmm:6:2-3:087  0.766
2004 Ferrante RJ, Ryu H, Kubilus JK, D'Mello S, Sugars KL, Lee J, Lu P, Smith K, Browne S, Beal MF, Kristal BS, Stavrovskaya IG, Hewett S, Rubinsztein DC, Langley B, et al. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 10335-42. PMID 15548647 DOI: 10.1523/Jneurosci.2599-04.2004  0.58
2004 Starkov AA, Fiskum G, Chinopoulos C, Lorenzo BJ, Browne SE, Patel MS, Beal MF. Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 7779-88. PMID 15356189 DOI: 10.1523/Jneurosci.1899-04.2004  0.407
2004 Browne SE, Beal MF. The energetics of Huntington's disease. Neurochemical Research. 29: 531-46. PMID 15038601 DOI: 10.1023/B:Nere.0000014824.04728.Dd  0.535
2004 Browne SE, Roberts LJ, Dennery PA, Doctrow SR, Beal MF, Barlow C, Levine RL. Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxia-telangiectasia mice. Free Radical Biology & Medicine. 36: 938-42. PMID 15019978 DOI: 10.1016/J.Freeradbiomed.2004.01.003  0.487
2004 Klivenyi P, Starkov AA, Calingasan NY, Gardian G, Browne SE, Yang L, Bubber P, Gibson GE, Patel MS, Beal MF. Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity. Journal of Neurochemistry. 88: 1352-60. PMID 15009635 DOI: 10.1046/J.1471-4159.2003.02263.X  0.766
2003 Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH, Browne SE, Shimizu Y, Joh TH, Beal MF, Albers DS. Minocycline enhances MPTP toxicity to dopaminergic neurons. Journal of Neuroscience Research. 74: 278-85. PMID 14515357 DOI: 10.1002/Jnr.10709  0.756
2003 Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. Journal of Neurochemistry. 86: 267-72. PMID 12807446 DOI: 10.1046/J.1471-4159.2003.T01-1-01868.X  0.786
2003 Wu AS, Kiaei M, Aguirre N, Crow JP, Calingasan NY, Browne SE, Beal MF. Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. Journal of Neurochemistry. 85: 142-50. PMID 12641736 DOI: 10.1046/J.1471-4159.2003.01639.X  0.672
2003 Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF. Erratum: Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease (Journal of Neurochemistry (2003) 86 (267-272)) Journal of Neurochemistry. 87. DOI: 10.1046/J.1471-4159.2003.01868.X  0.769
2002 Andreassen OA, Dedeoglu A, Stanojevic V, Hughes DB, Browne SE, Leech CA, Ferrante RJ, Habener JF, Beal MF, Thomas MK. Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiology of Disease. 11: 410-24. PMID 12586550 DOI: 10.1006/Nbdi.2002.0562  0.484
2002 Browne SE, Beal MF. Toxin-induced mitochondrial dysfunction. International Review of Neurobiology. 53: 243-79. PMID 12512343 DOI: 10.1016/S0074-7742(02)53010-5  0.447
2001 Jeitner TM, Bogdanov MB, Matson WR, Daikhin Y, Yudkoff M, Folk JE, Steinman L, Browne SE, Beal MF, Blass JP, Cooper AJ. N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. Journal of Neurochemistry. 79: 1109-12. PMID 11739625 DOI: 10.1046/J.1471-4159.2001.00673.X  0.434
2001 Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Ferrante KL, Thomas M, Friedlich A, Browne SE, Schilling G, Borchelt DR, Hersch SM, Ross CA, Beal MF. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiology of Disease. 8: 479-91. PMID 11447996 DOI: 10.1006/Nbdi.2001.0406  0.757
2000 Albers DS, Augood SJ, Park LC, Browne SE, Martin DM, Adamson J, Hutton M, Standaert DG, Vonsattel JP, Gibson GE, Beal MF. Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. Journal of Neurochemistry. 74: 878-81. PMID 10646541 DOI: 10.1046/J.1471-4159.2000.740878.X  0.459
1999 Simon DK, Pulst SM, Sutton JP, Browne SE, Beal MF, Johns DR. Familial multisystem degeneration with parkinsonism associated with the 11778 mitochondrial DNA mutation. Neurology. 53: 1787-93. PMID 10563629 DOI: 10.1212/Wnl.53.8.1787  0.556
1999 Polidori MC, Mecocci P, Browne SE, Senin U, Beal MF. Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex. Neuroscience Letters. 272: 53-6. PMID 10507541 DOI: 10.1016/S0304-3940(99)00578-9  0.599
1999 Browne SE, Ayata C, Huang PL, Moskowitz MA, Beal MF. The cerebral metabolic consequences of nitric oxide synthase deficiency: glucose utilization in endothelial and neuronal nitric oxide synthase null mice. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 19: 144-8. PMID 10027769 DOI: 10.1097/00004647-199902000-00005  0.47
1999 Browne SE, Ferrante RJ, Beal MF. Oxidative stress in Huntington's disease. Brain Pathology (Zurich, Switzerland). 9: 147-63. PMID 9989457 DOI: 10.1111/J.1750-3639.1999.Tb00216.X  0.55
1998 Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proceedings of the National Academy of Sciences of the United States of America. 95: 8892-7. PMID 9671775 DOI: 10.1073/Pnas.95.15.8892  0.662
1998 Browne SE, Bowling AC, Baik MJ, Gurney M, Brown RH, Beal MF. Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis. Journal of Neurochemistry. 71: 281-7. PMID 9648876 DOI: 10.1046/J.1471-4159.1998.71010281.X  0.63
1997 Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown RH. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Annals of Neurology. 42: 644-54. PMID 9382477 DOI: 10.1002/ana.410420416  0.454
1997 Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, Kowall NW, Brown RH, Beal MF. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. Journal of Neurochemistry. 69: 2064-74. PMID 9349552 DOI: 10.1046/J.1471-4159.1997.69052064.X  0.758
1997 Matthews RT, Ferrante RJ, Jenkins BG, Browne SE, Goetz K, Berger S, Chen IY, Beal MF. Iodoacetate produces striatal excitotoxic lesions. Journal of Neurochemistry. 69: 285-9. PMID 9202321 DOI: 10.1046/J.1471-4159.1997.69010285.X  0.415
1997 Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Annals of Neurology. 41: 646-53. PMID 9153527 DOI: 10.1002/ana.410410514  0.64
1995 Schulz JB, Matthews RT, Muqit MM, Browne SE, Beal MF. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. Journal of Neurochemistry. 64: 936-9. PMID 7530297 DOI: 10.1046/J.1471-4159.1995.64020936.X  0.618
1994 Browne SE, Beal MF. Oxidative damage and mitochondrial dysfunction in neurodegenerative diseases. Biochemical Society Transactions. 22: 1002-6. PMID 7698395  0.476
Show low-probability matches.